Pentixapharm Holding AG (FRA:PTP)

Market Cap	48.33M
Revenue (ttm)	137.00K
Net Income (ttm)	-16.86M
Shares Out	n/a
EPS (ttm)	-0.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	60,468
Average Volume	20,546
Open	2.055
Previous Close	2.075
Day's Range	1.922 - 2.060
52-Week Range	2.005 - 5.150
Beta	n/a
RSI	28.52
Earnings Date	Aug 7, 2025

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2019
• Employees: 75
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PTP